CytomX Therapeutics (CTMX) Q3 2024 earnings summary

Executive summary

• Advanced three clinical programs: CX-904 (T-cell engager), CX-2051 (EpCAM ADC), and CX-801 (interferon alpha-2b), all leveraging the PROBODY platform for masked, conditionally activated biologics, with a focus on safer, more effective cancer therapies.

• Initial Phase 1 data for CX-904 and CX-2051 show favorable safety and early efficacy signals; CX-801 dosed first patient in Q3 2024.

• No products approved for sale; revenue is from collaborations and milestone payments.

• Strong industry partnerships with Amgen, BMS, Moderna, Astellas, and Regeneron support ongoing research and development.

• Multiple clinical readouts expected in 2025 to inform later phase development and value creation.

Financial highlights

• Ended Q3 2024 with $117.6 million in cash, cash equivalents, and investments, down from $137.2 million at the end of Q2.

• Q3 2024 revenue was $33.4 million, up from $26.4 million in Q3 2023, driven by collaborations with BMS and Moderna.

• Net income for Q3 2024 was $5.7 million, up from $3.0 million in Q3 2023; diluted EPS was $0.07.

• R&D expenses rose to $21.4 million in Q3 2024, up $4.9 million year-over-year, mainly due to increased clinical and manufacturing spend for CX-2051 and CX-904.

• Cash runway expected to fund operations through the end of 2025, not including potential new milestones or business development.

Outlook and guidance

• Anticipates multiple clinical data readouts in 2025 for all three lead programs.

• Initial phase I-A update for CX-2051 expected in the first half of 2025; initial phase I-A data for CX-801 anticipated in the second half of 2025.

• No decision on phase I-B initiation for CX-904 expected in 2024; potential phase I-B in 2025 pending dose optimization and partner alignment.

• Ongoing focus on advancing clinical pipeline and expanding discovery programs across multiple modalities.

• Capital allocation remains disciplined, focused on advancing clinical milestones.